Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ionis Pharmaceuticals ( (IONS) ) has provided an update.
On May 19, 2025, Ionis Pharmaceuticals announced positive results from the Essence study of olezarsen, showing significant reductions in triglyceride levels in people with moderate hypertriglyceridemia. The study met its primary and secondary endpoints, demonstrating a favorable safety profile, and supports olezarsen’s potential for broader use in treating severe hypertriglyceridemia, with further data expected in Q3 2025.
The most recent analyst rating on (IONS) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.
Spark’s Take on IONS Stock
According to Spark, TipRanks’ AI Analyst, IONS is a Neutral.
Ionis Pharmaceuticals shows potential with strong recent product launches and increased revenue guidance, but it faces significant financial challenges, including high leverage and ongoing losses. The bullish technical indicators provide a positive short-term outlook, but the valuation remains a concern due to ongoing profitability issues.
To see Spark’s full report on IONS stock, click here.
More about Ionis Pharmaceuticals
Ionis Pharmaceuticals is a pioneer in RNA-targeted medicines, with a focus on neurology, cardiology, and other areas of high patient need. The company has a leading pipeline and has developed six marketed medicines, driving innovation in RNA therapies and gene editing.
Average Trading Volume: 1,720,827
Technical Sentiment Signal: Sell
Current Market Cap: $5.34B
For a thorough assessment of IONS stock, go to TipRanks’ Stock Analysis page.